| 28.03 Data as of 4:00pm ET |  +0.47 / +1.71%Today’s Change | 9.78 Today|||52-Week Range 28.68 | +53.59% Year-to-Date |
| Alnylam Narrows Loss, Sales Fall - Analyst Blog May 07 / Zacks.com |
| Previous close | 27.56 |
| Today’s open | 27.56 |
| Day’s range | 27.38 - 28.23 |
| Volume | 211,522 |
| Average volume (3 months) | 438,030 |
| Market cap | $1.7B |
| Dividend yield | -- |
| Earnings growth (last year) | -55.15% |
| Earnings growth (this year) | +38.66% |
| Earnings growth (next 5 years) | 0.00% |
| Revenue growth (last year) | -19.37% |
| P/E ratio | NM |
| Price/Sales | 13.75 |
| Price/Book | 10.79 |
| Today’s change | Today’s % change | |
|---|---|---|
| ABCOAdvisory Board Co | +0.80 | +1.59% |
| ICLRICON PLC | -0.03 | -0.09% |
| CRLCharles River Labora... | +0.08 | +0.18% |
| ISISIsis Pharmaceuticals... | +0.35 | +1.71% |
| Next reporting date | August 7, 2013 |
| EPS forecast (this quarter) | -$0.34 |
| Annual revenue (last year) | $66.7M |
| Annual profit (last year) | -$106.0M |
| Net profit margin | -158.88% |
Sector Health Technology |
Industry Biotechnology |
Chairman John K. Clarke, MBA |
President & Chief Operating Officer Barry E. Greene |
Corporate headquarters Cambridge, Massachusetts |
.
